3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Endocrine
1
Conditions
Carcinoma, Transitional Cell
14
Urinary Bladder Neoplasms
13
Colorectal Neoplasms
10
Carcinoma, Merkel Cell
9
Breast Neoplasms
9
Carcinoma, Renal Cell
7
Neoplasms
6
Neoplasm Metastasis
6
Carcinoma, Non-Small-Cell Lung
6
Small Cell Lung Carcinoma
4
Carcinoma, Hepatocellular
4
Turcot syndrome
3
Stomach Neoplasms
3
Neuroendocrine Tumors
3
Head and Neck Neoplasms
3
Endometrial Neoplasms
3
Urethral Neoplasms
2
Ureteral Neoplasms
2
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Penile Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Melanoma
2
Lung Neoplasms
2
Glioblastoma
2
Gastrointestinal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Squamous Cell
2
Carcinoma, Neuroendocrine
2
Uterine Cervical Neoplasms
1
Interventions
Rituximab
130
Cyclophosphamide
113
Peripheral Blood Stem Cell Transplantation
59
fludarabine phosphate
55
Etoposide
47
Mycophenolic Acid
44
Radiotherapy
41
Filgrastim
41
Tacrolimus
40
Whole-Body Irradiation
36
Busulfan
34
Melphalan
33
Cyclosporine
30
Cytarabine
29
Methotrexate
28
sargramostim
27
Vincristine
27
Antilymphocyte Serum
27
Prednisone
26
Lenalidomide
23
obinutuzumab
22
Doxorubicin
22
Carmustine
21
Bortezomib
20
Methylprednisolone
19
fludarabine
17
Dexamethasone
17
Bendamustine Hydrochloride
17
ibritumomab tiuxetan
15
Cord Blood Stem Cell Transplantation
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Lymphoma, Follicular
×
avelumab
×
Clear all
NCT03147404
2019-12-30
MS100070-0177
Samsung Medical Center
Phase 2
Completed
14 enrolled